Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT06400472 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Start date: May 6, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

NCT ID: NCT06393166 Recruiting - Clinical trials for Non-Resectable Pancreas Carcinoma

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

It is a single arm, open-label, multicenter, phase II cinical trial to evaluate the efficacy and safety of the Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection in first-line treatment of patients with Advanced or Metastatic Pancreatic Cancer.

NCT ID: NCT06391892 Recruiting - Pancreatic Cancer Clinical Trials

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

LIQUIPANC
Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

NCT ID: NCT06389760 Recruiting - Pancreatic Cancer Clinical Trials

Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Start date: October 18, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, single-arm, phase II trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX for postoperative adjuvant treatment of pancreatic cancer.

NCT ID: NCT06388967 Recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Detection Consortium

PCDC
Start date: March 15, 2023
Phase:
Study type: Observational

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

NCT ID: NCT06378047 Recruiting - Pancreatic Cancer Clinical Trials

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).

NCT ID: NCT06368063 Recruiting - Clinical trials for Pancreatic Cancer Resectable

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Start date: May 6, 2024
Phase: Phase 4
Study type: Interventional

The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer

NCT ID: NCT06361888 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Start date: May 8, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

NCT ID: NCT06361316 Recruiting - Pancreatic Cancer Clinical Trials

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.

NCT ID: NCT06360354 Recruiting - Clinical trials for Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Start date: May 29, 2024
Phase: Phase 1
Study type: Interventional

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.